XML 41 R22.htm IDEA: XBRL DOCUMENT
v3.22.4

Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Revenue from Significant Partners | Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:
| Year ended December 31,
| 2022 |  | 2021(a) |  | 2020(a)
Partner A | 45% |  | 47% |  | 51%
Partner B | 16% |  | 12% |  | 17%
Partner C | <10% |  | <10% |  | <10%
(a) Prior period amounts have been retrospectively adjusted to reflect the effects of the Separation.
Schedule of Commercial License Rights | As of December 31, 2022 and 2021, commercial license and other economic rights consist of the following (in thousands):
|  | December 31, 2022 |  | December 31, 2021
|  | Gross |  | Adjustments(1) |  | Net |  | Gross |  | Adjustments(2) |  | Net
Aziyo and CorMatrix |  | $ | 17,696 |  |  | $ | (9,538) |  |  | $ | 8,158 |  |  | $ | 17,696 |  |  | $ | (9,461) |  |  | $ | 8,235 |
Selexis and Dianomi |  | 10,602 |  |  | (8,578) |  |  | 2,024 |  |  | 10,602 |  |  | (8,727) |  |  | 1,875 |
Total |  | $ | 28,298 |  |  | $ | (18,116) |  |  | $ | 10,182 |  |  | $ | 28,298 |  |  | $ | (18,188) |  |  | $ | 10,110 |
(1) Amounts represent accumulated amortization to principal of $11.6 million and credit loss adjustments of $6.5 million as of December 31, 2022. (2) Amounts represent accumulated amortization to principal of $11.7 million and credit loss adjustments of $6.5 million as of December 31, 2021.
Schedule of Disaggregation of Revenue | Royalty revenue for 2022, 2021 and 2020 for continuing operations are reported as below (in thousands):
|  | Year ended December 31,
|  | 2022 |  | 2021 |  | 2020
Kyprolis |  | $ | 30,116 |  |  | $ | 27,472 |  |  | $ | 25,164 |
Evomela |  | 10,197 |  |  | 10,079 |  |  | 6,377 |
Teriparatide injection |  | 15,785 |  |  | 5,260 |  |  | — |
Rylaze |  | 8,796 |  |  | 2,420 |  |  | — |
Other |  | 7,633 |  |  | 3,696 |  |  | 2,255 |
|  | $ | 72,527 |  |  | $ | 48,927 |  |  | $ | 33,796 |
The following table represents disaggregation of Captisol and contract revenue for continuing operations (in thousands):
|  | Year ended December 31,
|  | 2022 |  | 2021 |  | 2020
Captisol |  |  |  |  |  |
Captisol - Core |  | $ | 16,429 |  |  | $ | 23,423 |  |  | $ | 24,566 |
Captisol - COVID(a) |  | 88,066 |  |  | 140,827 |  |  | 85,393 |
|  | $ | 104,495 |  |  | $ | 164,250 |  |  | $ | 109,959 |
Contract |  |  |  |  |  |
Service Revenue |  | $ | 1,117 |  |  | $ | 3,737 |  |  | $ | 9,330 |
License Fees |  | 2,849 |  |  | 634 |  |  | 119 |
Milestone |  | 9,150 |  |  | 17,584 |  |  | 5,217 |
Other |  | 6,107 |  |  | 6,412 |  |  | 5,141 |
|  | $ | 19,223 |  |  | $ | 28,367 |  |  | $ | 19,807 |
(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.
Schedule of Computation of Basic and Diluted Net Income (Loss) per Share | The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):
| Year Ended December 31,
| 2022 |  | 2021 |  | 2020
Weighted average shares outstanding: | 16,868 |  |  | 16,630 |  |  | 16,185 |
Dilutive potential common shares: |  |  |  |  |
Restricted stock | — |  |  | 96 |  |  | 56 |
Stock options | — |  |  | 520 |  |  | 584 |
Shares used to compute diluted income per share | 16,868 |  |  | 17,246 |  |  | 16,825 |
Potentially dilutive shares excluded from calculation due to anti-dilutive effect | 6,241 |  |  | 4,793 |  |  | 8,458 |

X
- Definition Schedule of Commercial License Rights [Table Text Block] + References No definition available. + Details
Name: | lgnd_ScheduleofCommercialLicenseRightsTableTextBlock
Namespace Prefix: | lgnd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration